The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in diabetes patients.
Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, according to a new analysis of electronic health records.
That's because by the time many patients are diagnosed with the disease,"it's often too late for treatment," Xu told CNBC. She added that many of the risk factors of Alzheimer's, such as obesity, diabetes and smoking, are preventable and"modifiable." The study compared semaglutide with seven different diabetes medications, including insulin and a drug called metformin. It also includes other GLP-1s, such as liraglutide and a medication from Eli Lilly called dulaglutide.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study saysThe results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.
Read more »
Novo Nordisk CEO Defends High Ozempic, Wegovy Prices at Congressional HearingNovo Nordisk CEO Lars Jorgensen faced intense scrutiny from lawmakers on Tuesday over the high prices of the company's weight-loss drugs Ozempic and Wegovy. Jorgensen argued that pharmacy benefit managers (PBMs) are responsible for a significant portion of drug costs, but lawmakers pressed him to take action to lower prices for American patients.
Read more »
Senate Panel Probes Novo Nordisk Over High Ozempic, Wegovy PricesA U.S. Senate committee grilled Novo Nordisk CEO Lars Jorgensen about the exorbitant prices of the company's weight-loss drugs Ozempic and Wegovy. Lawmakers demanded answers and explored potential solutions to make these life-changing medications more affordable.
Read more »
Novo Nordisk CEO Grilled Over High Ozempic and Wegovy PricesLawmakers grilled Novo Nordisk CEO Lars Jorgensen over the high cost of weight-loss drugs Ozempic and Wegovy during a Tuesday hearing. Jorgensen placed some blame on pharmacy benefits managers, claiming they take 74 cents of every dollar the company makes.
Read more »
Novo Nordisk CEO Grilled Over High Prices of Weight-Loss Drugs Ozempic and WegovyDuring a Congressional hearing, Novo Nordisk CEO Lars Jorgensen faced pressure from lawmakers regarding the high prices of weight-loss drugs Ozempic and Wegovy. While Jorgensen attributed some costs to pharmacy benefit managers, he agreed to meet with them to discuss potential price reductions.
Read more »
Novo Nordisk CEO Grilled by Congress Over Price of OzempicDuring a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jorgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.
Read more »